A Randomized, Double-Blind, Placebo-Controlled, Multi-center Phase III Clinical Study to Evaluate the Efficacy and Safety of FCN-159 in Adult Patients with Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Luvometinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Fosun Pharmaceutical Development
Most Recent Events
- 06 Mar 2025 Planned primary completion date changed from 30 Jun 2025 to 19 Aug 2025.
- 06 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 26 Feb 2024 Status changed from not yet recruiting to recruiting.